Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

We believe that California-based The Clorox Company (CLX - Analyst Report), through its plans for further acquisitions and willingness to grab alliance opportunities, will boost its market share and product portfolio. Moreover, the company recently posted better-than-expected fourth-quarter 2012 results. Driven by these factors, we have upgraded our long-term recommendation on the stock to ‘Outperform’ from ‘Neutral’.

In the recently reported quarter, Clorox posted earnings of $1.36 per share, ahead of the Zacks Consensus Estimate of $1.27, and up 5.4% from the prior-year period’s earnings. Sales for the quarter grew 4% year over year to $1,541 million and also surpassed the Zacks Consensus Estimate of $1,534 million.

The encouraging results were driven by benefits from cost-saving initiatives, higher volumes, price increases, lower advertising costs and tax rate. Additionally, contributions from new businesses, which were acquired earlier in the year, drove sales higher. Strong results as well as innovations across its brands prompted management to guide fiscal 2013 sales growth in the range of 2% - 4% and earnings per share between $4.20 and $4.35.

Clorox is one of the world's leading manufacturers of consumer products. Furthermore, the company possesses a strong portfolio of brands, including Clorox, Glad, Brita, Armor All, Burt’s Bees, STP and Kingsford, which offer a competitive edge to the company and bolster its well-established position in the market.

Clorox has expanded its capabilities in the areas of health and wellness by acquiring Aplicare Inc. and HealthLink, providers of infection control products in the healthcare industry. The company sees ample growth potential in the use of infection control products. We believe that the acquisition has not only strengthened its product offerings, but also its expertise, R&D and sales capabilities.

Clorox is making intensive capital investments in information technology systems and capabilities, particularly in the international market, and R&D facilities to boost productivity while providing platforms for growth, product innovation and cost savings. The company believes that these initiatives will begin delivering benefits later in fiscal 2014 and beyond.

Based on the above analysis and its strong fundamental outlook, we expect Clorox to continue accelerating revenue and earnings growth over the next few quarters. Our new long-term ‘Outperform’ recommendation is supported by a Zacks #2 Rank (short-term Buy rating).

Clorox competes with Colgate-Palmolive Company (CL - Analyst Report) and Procter and Gamble Company (PG - Analyst Report).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%